Catalyst
Slingshot members are tracking this event:
Puma Biotechnology Announces European Medicines Agency Validation of Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PBYI |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 22, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Neratinib, Pb272, Her2-positive Breast Cancer, Marketing Authorization, European Medicines Agency
